The MATTERHORN trial was a global, Phase 3 study that investigated the addition of Durvalumab (an immunotherapy drug) to the standard FLOT chemotherapy regimen in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial aimed to evaluate whether this combination could improve survival outcomes and pathological responses.
The MATTERHORN trial was a global, Phase 3 study that investigated the addition of Durvalumab (an immunotherapy drug) to the standard FLOT chemotherapy regimen in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial aimed to evaluate whether this combination could improve survival outcomes and pathological responses.
Participants were randomized into two groups: one received Durvalumab (1500 mg) combined with FLOT chemotherapy, while the other received a placebo with FLOT. FLOT chemotherapy was administered every two weeks for 4 cycles before surgery (neoadjuvant) and 2 cycles after surgery (adjuvant). After surgery, patients continued with Durvalumab or placebo every 4 weeks for up to 10 additional cycles, extending the immunotherapy treatment.
The primary endpoint of the trial was Event-Free Survival (EFS), while secondary endpoints included pathological complete response (pCR), major pathological response (MPR), and Overall Survival (OS). PD-L1 expression (a biomarker) was also analyzed to assess its impact on treatment outcomes.
Results showed that the combination of Durvalumab + FLOT significantly improved OS, with a 22% reduction in the risk of death compared to placebo + FLOT. EFS also improved, particularly in patients achieving a pathological response. Additionally, nodal downstaging (reduction in cancer spread to lymph nodes) was more frequent in the Durvalumab group (58.2% vs 44.8%). Importantly, the survival benefits were consistent across both high and low PD-L1 expression groups.
The study concluded that Durvalumab + FLOT chemotherapy provides a meaningful survival benefit and may set a new standard of care for resectable gastric and GEJ adenocarcinomas.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.